Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

China Arrests GM, Others Of Maker Of Tainted Human Rabies Vaccine

This article was originally published in PharmAsia News

Executive Summary

Chinese authorities arrested three Dalian Jingang-Andi Bio-products employees, including two senior executives, for alleged fraud in producing a human rabies vaccine containing a banned ingredient. Arrested were the company's general manager, his deputy and a purchasing agent. China's State FDA requested the arrests after the firm was found to have deliberately included nucleic acid in the anti-rabies compound over a five-month period last year. Authorities also ordered confiscated the company's earnings from the 360,200 doses of the vaccine that have been recalled. (Click here for more

You may also be interested in...



French Experts Call For Pseudoephedrine Reverse-Switch

Two leading, independent bodies of French scientists, doctors and pharmacists are calling for OTC drugs containing pseudoephedrine to be reverse-switched to prescription-only status over safety fears.

OTC Innovation In An Age Of Pandemics – Q&A With Stada’s New R&D Head Stephen Makin

COVID-19 has shifted consumer health behaviour towards prevention and general wellbeing. However, finding out what consumers actually want and need is still the essence of good OTC innovation, according to Stada Arzneimittel's new vice president of consumer healthcare product development Steve Makin.

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.

UsernamePublicRestriction

Register

LL1127674

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel